Novel HIV ART
Optimizing ART With Novel HIV Agents

Released: August 19, 2024

Expiration: August 18, 2025

Gregory Huhn
Gregory Huhn, MD, MPHTM

Activity

Progress
1
Course Completed

In this episode, Gregory Huhn, MD, MPHTM, presents a case study of a person with a long HIV treatment history, exploring when and how to consider agents with novel mechanisms of action.

Listen as he discusses:

  • The importance of engaging with patients to understand their perspectives and improve their satisfaction with their HIV care
  • Options in people with multiclass resistance
  • Studies of agents with novel mechanisms of action:
    • BRIGHTE (fostemsavir)
    • TMB-301/-311 (ibalizumab)
    • CAPELLA (lenacapavir)